Rani Therapeutics Holdings Inc (RANI) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Rani Therapeutics Holdings Inc $0.20, price $0.77, upside -73.4%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Rani Therapeutics Holdings Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.4100 – $35.00 · fair‑value band $0.1360 – $0.2550 · the $0.7670 price screens above the $0.2040 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Rani Therapeutics Holdings in your weekly email
Every Wednesday you see whether Rani Therapeutics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Show more
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Stock analysis
Rani Therapeutics Holdings Inc (RANI) currently trades at $0.7670, while our model-based Fair Value estimate is $0.2040, implying the stock looks roughly 275.9% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 81/100, which puts the evidence level at low.
Scenario range: $0.1360 (bear) to $0.2550 (bull), the price of $0.7670 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Rani Therapeutics Holdings Inc reported revenue of $1.6M in FY2025 versus $2.7M in FY2021, a compound −12.0%/yr. Reported net income was −$29.7M in FY2025.
Key figures
Market cap $144M · P/S ratio 24.8 · EPS (TTM) $−0.1300 · Return on equity −172% · Return on assets (EBIT) −85.1% · Operating margin −517% · Revenue (TTM) $4.9M · Revenue growth (YoY) +893%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 73% below its 52-week high and 67% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −73%, RANI screens richer than that median.
Fair Value models
Bear $0.1360Fair Value $0.2040Bull $0.2550
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+58.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
’19
’20
’21
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,581.0% (2020) → −2,346.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Rani Therapeutics Holdings Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Below median
Fair Value upside−73% · Bottom 25%
Profitability
Return on assets−53% · Bottom 25%
Growth and dividend
Revenue growth893% · Top 25%
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B4.35× · Priciest 25%
P/S (TTM)29.44× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)85· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Rani Therapeutics Holdings Inc (RANI) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.2040 versus a price of $0.7670, about −73% upside (overvalued).
What is the fair value of RANI?
Our model-based fair value for Rani Therapeutics Holdings Inc is $0.2040 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.7670.
What is the quality score of RANI?
Rani Therapeutics Holdings Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rani Therapeutics Holdings Inc (RANI)?
Our model-based price target is the fair value of $0.2040 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.1360, optimistic scenario $0.2550. It is a calculation from audited fundamentals, not an analyst target.
What is the Rani Therapeutics Holdings Inc stock forecast for 2026?
Our models put fair value at $0.2040, about −73% upside versus a price of $0.7670 (overvalued). Cautious scenario $0.1360, optimistic scenario $0.2550. The calculation is refreshed regularly with new filings.
What is the revenue of Rani Therapeutics Holdings Inc (RANI)?
Rani Therapeutics Holdings Inc reported trailing-twelve-month revenue of about $4.9M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Rani Therapeutics Holdings Inc (RANI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rani Therapeutics Holdings Inc it is $0.2040 per share (as of Sep 23, 2026), against a price of $0.7670. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Rani Therapeutics Holdings Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, RANI trades above its calculated fair value: price $0.7670, fair value $0.2040, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RANI?
No. The price is what the market pays today ($0.7670); the fair value is what the company's own numbers justify ($0.2040). For Rani Therapeutics Holdings Inc the two are $0.5630 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rani Therapeutics Holdings Inc worth?
The market values Rani Therapeutics Holdings Inc at about $144M (market capitalisation, as of Sep 23, 2026). Per share that is $0.7670; our models calculate a fair value of $0.2040 per share.
What do the bullish and bearish scenarios say about RANI?
Our models span a range for Rani Therapeutics Holdings Inc: cautious scenario $0.1360, base $0.2040, optimistic $0.2550 per share (as of Sep 23, 2026, price $0.7670). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rani Therapeutics Holdings Inc (RANI)?
Balance-sheet figures for Rani Therapeutics Holdings Inc (as of Sep 23, 2026): return on equity −172.2%, debt of 0.29 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is RANI from its 52-week high?
Rani Therapeutics Holdings Inc trades at $0.7670, about 73% below its 52-week high of $2.85 and 67% above the low of $0.4580 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2040 is for.
Which stocks are comparable to Rani Therapeutics Holdings Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rani Therapeutics Holdings Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.7670, calculated fair value $0.2040 (−73%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RANI calculated?
We run Rani Therapeutics Holdings Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2040, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Rani Therapeutics Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rani Therapeutics Holdings Inc (RANI)?
The closing price on Sep 23, 2026 was $0.7670. Our model-based fair value is $0.2040, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rani Therapeutics Holdings Inc right now?
The price sits above even our optimistic bull case ($0.2550). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1360 to $0.2550) leaves room in how you read the outcome.
Key figures of Rani Therapeutics Holdings Inc
How large is the market capitalisation of Rani Therapeutics Holdings Inc (RANI)?
The market capitalisation of Rani Therapeutics Holdings Inc is $144M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rani Therapeutics Holdings Inc (RANI)?
The price-to-sales ratio of Rani Therapeutics Holdings Inc is 24.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rani Therapeutics Holdings Inc (RANI)?
Earnings per share at Rani Therapeutics Holdings Inc are $−0.1300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Rani Therapeutics Holdings Inc (RANI)?
The return on equity (ROE) of Rani Therapeutics Holdings Inc is −172% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rani Therapeutics Holdings Inc (RANI)?
On an EBIT basis the return on assets of Rani Therapeutics Holdings Inc is −85.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rani Therapeutics Holdings Inc (RANI)?
The operating margin of Rani Therapeutics Holdings Inc is −517% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rani Therapeutics Holdings Inc (RANI)?
Revenue at Rani Therapeutics Holdings Inc is growing +893% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rani Therapeutics Holdings Inc (RANI) generate?
The free cash flow of Rani Therapeutics Holdings Inc is −$18.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rani Therapeutics Holdings Inc (RANI) hold?
Rani Therapeutics Holdings Inc holds more cash than debt, $14.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Rani Therapeutics Holdings Inc in the live analysis
One click puts Rani Therapeutics Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026